Exelixis Inc. buy klostergang
Start price
29.01.18
/
50%
€27.35
Target price
29.01.19
€35.18
Performance (%)
-23.88%
End price
29.01.19
€20.82
Summary
This prediction ended on 29.01.19 with a price of €20.82. The price of Exelixis Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.88%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | -3.344% | -3.344% | 19.886% | 145.748% |
| iShares Core DAX® | -1.673% | 2.237% | 16.344% | 61.776% |
| iShares Nasdaq 100 | -1.346% | 0.290% | 3.851% | 105.171% |
| iShares Nikkei 225® | -1.529% | 5.863% | 18.286% | 52.222% |
| iShares S&P 500 | -1.702% | 0.697% | 1.755% | 66.580% |
Comments by klostergang for this prediction
In the thread Exelixis Inc. diskutieren
klostergang stimmt der Buy-Einschätzung von stratec zu
klostergang stimmt am 29.01.2018 der Buy-Einschätzung von stratec mit dem Kursziel 34$ zu.
Überschrift: EXEL is currently becoming a key player in the kidney cancer space
Update:
The stock sold off after fourth-quarter earnings, but the long-term thesis appears intact as label expansion for cabozantinib and other bullish drivers should kick in in the medium term. Near-term weakness, long-term outperformance is my initial impression.
(Laufzeit überschritten)